Why Eli Lilly Remains My Top Obesity Bet

Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $11.7 billion in Q4. Meanwhile, on March 19, Eli Lilly published promising clinical data on retatrutide for the treatment of type 2 diabetes.